Attached files
file | filename |
---|---|
8-K - RADIENT PHARMACEUTICALS Corp | v207545_8-k.htm |
|
RPC
Contact:
Kristine
Szarkowitz
Director-Investor
Relations
kszarkowitz@radient-pharma.com
(Tel
:) 206.310.5323
|
RADIENT
PHARMACEUTICALS RECEIVES NYSE AMEX APPROVAL FOR DEBT TO EQUITY
EXCHANGE
According
to RPC Chairman and CEO Douglas MacLellan, “We are pleased with the NYSE Amex
approval and believe this sets the Company and on a solid path for the future
growth and financial stability. Based upon shareholder and NYSE Amex
approval of the various note transactions, warrant conversions and debt
exchange agreements, RPC is in a position to have up to approximately $27
million in debt and $14 million in other liabilities eliminated. As a
result, we anticipate an increase of approximately $41 million in total
shareholder’s equity.”
For
additional information on Radient Pharmaceuticals Corporation and its products
visit: www.radient-pharma.com
or send e-mail to info@radient-pharma.com. For Investor Relations contact
Kristine Szarkowitz at IR@RadientPharma.com or 1.206.310.5323.
About Radient
Pharmaceuticals:
Forward Looking
Statements:
Safe
Harbor Statement under the Private Securities Litigation Reform Act of 1995: The
statements contained in this document include certain predictions and
projections that may be considered forward-looking statements under securities
law. These statements involve a number of important risks and uncertainties that
could cause actual results to differ materially including, but not limited to,
the performance of joint venture partners, as well as other economic,
competitive and technological factors involving the Company’s operations,
markets, services, products, and prices. With respect to Radient
Pharmaceuticals Corporation, except for the historical information contained
herein, the matters discussed in this document are forward-looking statements
involving risks and uncertainties that could cause actual results to differ
materially from those in such forward-looking statements.